Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $178,500.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $28.56, for a total transaction of $178,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00.
• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $34,937.70.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.33, for a total transaction of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.54, for a total transaction of $95,795.00.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $27.63 on Friday. The company’s fifty day simple moving average is $25.24 and its 200-day simple moving average is $23.26. The stock has a market capitalization of $1.31 billion, a PE ratio of -14.32 and a beta of 1.10. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. As a group, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Quest Partners LLC lifted its stake in shares of Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after buying an additional 742 shares in the last quarter. EntryPoint Capital LLC purchased a new position in shares of Enliven Therapeutics during the 1st quarter valued at $167,000. China Universal Asset Management Co. Ltd. increased its holdings in Enliven Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after acquiring an additional 3,559 shares during the last quarter. SG Americas Securities LLC bought a new stake in Enliven Therapeutics in the 3rd quarter valued at $256,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Enliven Therapeutics in the 2nd quarter valued at $322,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.